| ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering T Gaj, CA Gersbach, CF Barbas Trends in biotechnology 31 (7), 397-405, 2013 | 5022 | 2013 |
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers IB Hilton, AM D'ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, ... Nature biotechnology 33 (5), 510-517, 2015 | 2199 | 2015 |
| RNA-guided gene activation by CRISPR-Cas9–based transcription factors P Perez-Pinera, DD Kocak, CM Vockley, AF Adler, AM Kabadi, ... Nature methods 10 (10), 973-976, 2013 | 1738 | 2013 |
| The next generation of CRISPR–Cas technologies and applications A Pickar-Oliver, CA Gersbach Nature reviews Molecular cell biology 20 (8), 490-507, 2019 | 1415 | 2019 |
| In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy CE Nelson, CH Hakim, DG Ousterout, PI Thakore, EA Moreb, RMC Rivera, ... Science 351 (6271), 403-407, 2016 | 1393 | 2016 |
| Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements PI Thakore, AM D'ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, ... Nature methods 12 (12), 1143-1149, 2015 | 1057 | 2015 |
| Genome-editing technologies for gene and cell therapy ML Maeder, CA Gersbach Molecular therapy 24 (3), 430-446, 2016 | 851 | 2016 |
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation LR Polstein, CA Gersbach Nature chemical biology 11 (3), 198-200, 2015 | 734 | 2015 |
| Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy DG Ousterout, AM Kabadi, PI Thakore, WH Majoros, TE Reddy, ... Nature communications 6 (1), 6244, 2015 | 565 | 2015 |
| Editing the epigenome: technologies for programmable transcription and epigenetic modulation PI Thakore, JB Black, IB Hilton, CA Gersbach Nature methods 13 (2), 127-137, 2016 | 520 | 2016 |
| CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, ... Nature biotechnology 35 (6), 561-568, 2017 | 488 | 2017 |
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector AM Kabadi, DG Ousterout, IB Hilton, CA Gersbach Nucleic acids research 42 (19), e147-e147, 2014 | 462 | 2014 |
| Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy CE Nelson, Y Wu, MP Gemberling, ML Oliver, MA Waller, JD Bohning, ... Nature medicine 25 (3), 427-432, 2019 | 431 | 2019 |
| Increasing the specificity of CRISPR systems with engineered RNA secondary structures DD Kocak, EA Josephs, V Bhandarkar, SS Adkar, JB Kwon, CA Gersbach Nature biotechnology 37 (6), 657-666, 2019 | 350 | 2019 |
| Synergistic and tunable human gene activation by combinations of synthetic transcription factors P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, ... Nature methods 10 (3), 239-242, 2013 | 339 | 2013 |
| The once and future gene therapy K Bulaklak, CA Gersbach Nature communications 11 (1), 1-4, 2020 | 305 | 2020 |
| How vinculin regulates force transmission DW Dumbauld, TT Lee, A Singh, J Scrimgeour, CA Gersbach, EA Zamir, ... Proceedings of the National Academy of Sciences 110 (24), 9788-9793, 2013 | 298 | 2013 |
| Advances in targeted genome editing P Perez-Pinera, DG Ousterout, CA Gersbach Current opinion in chemical biology 16 (3-4), 268-277, 2012 | 265 | 2012 |
| Targeted epigenetic remodeling of endogenous loci by CRISPR/Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells JB Black, AF Adler, HG Wang, AM D’Ippolito, HA Hutchinson, TE Reddy, ... Cell stem cell 19 (3), 406-414, 2016 | 252 | 2016 |
| A CRISPR/Cas9-based system for reprogramming cell lineage specification S Chakraborty, HY Ji, AM Kabadi, CA Gersbach, N Christoforou, ... Stem cell reports 3 (6), 940-947, 2014 | 246 | 2014 |
Timothy E ReddyAssociate Professor, Duke University確認したメール アドレス: duke.edu